Biopharma firms are increasingly choosing to manufacture their newer FDA-approved innovator and biosimilar products at facilities in China.
Despite Dr Heidi Overton’s declaration, senators questioned whether the commissioner-elect would challenge erroneous statements from president Trump.
Sandoz’s chief commercial officer discusses the company’s ambitious plans to have a biosimilar-driven growth engine by 2040.
The cash will primarily fund Enveda’s continued development of three clinical-stage assets for inflammatory and metabolic disorders.
Boehringer Ingelheim and Envisagenics have entered into a research collaboration and option agreement aimed at validating tumour-specific targets for the development of precision therapies in solid ...
Novo is shaping a future beyond its Wegovy franchise as CEO Maziar Mike Doustdar looks to turn the drugmaker’s fortunes around.
Made Scientific has acquired an 85,000ft² cell therapy manufacturing facility in Pennsylvania, US, from National Resilience.
Obicetrapib is being developed as a low-dose, oral CETP inhibitor for lowering LDL cholesterol in patients unresponsive to treatments. Credit: PeopleImages / Shutterstock.com. The European Commission ...
Outlining a five-year biomedical plan, China wants to expand its global role beyond just pipeline innovation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results